Emery Pharma Recognized in Leading Cancer Research Article
September 9, 2024 – Emery Pharma is proud to announce that Emery Pharma and Dr. Prajita Pandey, have been recognized for their contribution in a recent Genetic Engineering & Biotechnology News (GEN) article, titled “Better Biomarkers for Better Medicines.” The article explores cutting-edge advancements in cancer research and the development of more effective biomarkers for precision medicine.
Emery Pharma’s scientist team shared their insights on the role of biomarkers in the development of targeted cancer therapies were highlighted as part of Emery Pharma’s ongoing efforts to drive innovation in drug development research, biomarker development, and contributing to advancements that aim to improve patient outcomes and the future of precision medicine.
For the full article, please visit: https://www.genengnews.com/topics/cancer/better-biomarkers-for-better-medicines/
About Emery Pharma: As a Contract Research Organization (CRO) with expertise in bioanalysis and therapeutic development, Emery Pharma is dedicated to expediting the journey to a cure through innovative science and comprehensive data analysis.
